Patents by Inventor Nick Giannoukakls

Nick Giannoukakls has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7884085
    Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: February 8, 2011
    Assignees: Baxter International Inc., Baxter Healthcare S.A., University of Pittsburgh-of the Commonwealth System of Higher Education
    Inventors: Larry R. Brown, Vered Bisker-Leib, Terrence L. Scott, Debra Lafreniere, Jennifer Machen, Nick Giannoukakls
  • Publication number: 20060024240
    Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
    Type: Application
    Filed: May 12, 2005
    Publication date: February 2, 2006
    Inventors: Larry Brown, Vered Bisker-Leib, Terrence Scott, Debra Lafreniere, Jennifer Mochen, Nick Giannoukakls